Muller B, Stoclet J C, Lugnier C
Laboratoire de Pharmacologie Cellulaire et Moléculaire, Faculté de Pharmacie, Université Louis Pasteur de Strasbourg, CNRS URA 600, Illkirch, France.
Eur J Pharmacol. 1992 Mar 12;225(3):263-72. doi: 10.1016/0922-4106(92)90028-t.
Cyclic nucleotide phosphodiesterase (PDE) activities were characterized in the cytosolic and post-nuclear membrane preparations of guinea pig cardiac ventricles. The cytosolic PDE activities were stimulated 5-fold by calmodulin (CaM) on both substrates (1 microM) and 1.2-fold by cGMP (5 microM) on cAMP hydrolysis. Conversely, in the membrane preparation, CaM only stimulated PDE activities 1.2- to 1.4-fold, but cGMP induced a 3-fold increase of the hydrolysis of cAMP. In both the cytosolic and the membrane preparations, the hydrolysis of cAMP was inhibited by 100 microM of either the PDE III inhibitor SK&F 94120 (27% and 31% respectively) or the PDE IV inhibitor rolipram (14% and 23% respectively). Four peaks were resolved from the cytosolic preparation by chromatography. Peak A and peak B hydrolyzed both cAMP and cGMP and were stimulated respectively by CaM and cGMP. Peak C and peak D selectively hydrolyzed cAMP. Peak C had an apparent Km value for cAMP of 3.3 microM and was inhibited by PDE IV inhibitors. Peak D showed an apparent Km value for cAMP of 0.43 microM and was inhibited by cGMP and by cardiotonic inhibitors of PDE III. Similar potencies of these inhibitors were observed in the membrane preparation. These results suggest that in guinea pig cardiac ventricles: (1) PDE I (CaM-activated) is almost exclusively cytosolic; (2) PDE II (cGMP-stimulated), PDE III (cGMP-inhibited and cardiotonic-sensitive) and PDE IV (rolipram-sensitive) are present in cytosolic and membrane preparations; (3) PDE III and PDE IV differ in their apparent Km values for cAMP. The latter observation could explain the differential effects of PDE III and PDE IV inhibitors in the regulation of cardiac contraction.
对豚鼠心室的胞质和核后膜制剂中的环核苷酸磷酸二酯酶(PDE)活性进行了表征。在两种底物(1微摩尔)上,钙调蛋白(CaM)使胞质PDE活性提高了5倍,而在cAMP水解过程中,5微摩尔的cGMP使其提高了1.2倍。相反,在膜制剂中,CaM仅使PDE活性提高了1.2至1.4倍,但cGMP使cAMP水解增加了3倍。在胞质和膜制剂中,100微摩尔的PDE III抑制剂SK&F 94120(分别为27%和31%)或PDE IV抑制剂咯利普兰(分别为14%和23%)均可抑制cAMP的水解。通过色谱法从胞质制剂中分离出四个峰。峰A和峰B可水解cAMP和cGMP,分别受CaM和cGMP刺激。峰C和峰D选择性地水解cAMP。峰C对cAMP的表观Km值为3.3微摩尔,受PDE IV抑制剂抑制。峰D对cAMP的表观Km值为0.43微摩尔,受cGMP和PDE III的强心抑制剂抑制。在膜制剂中观察到这些抑制剂具有相似的效力。这些结果表明,在豚鼠心室中:(1)PDE I(CaM激活型)几乎完全存在于胞质中;(2)PDE II(cGMP刺激型)、PDE III(cGMP抑制型和强心敏感型)和PDE IV(咯利普兰敏感型)存在于胞质和膜制剂中;(3)PDE III和PDE IV对cAMP的表观Km值不同。后一观察结果可以解释PDE III和PDE IV抑制剂在心脏收缩调节中的不同作用。